Therapeutic Drug Monitoring · 1998 · 110 citations · 11 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyPsychiatric PharmacotherapyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyDrug DispositionDrug ToxicityPsychiatric Effects Of MedicationsAntipsychotic PharmacokineticsAntipsychotic Side EffectsConcentration-to-dose Ratio InterpretationCyp2d6 Drug MetabolismCyp2d6 PharmacogeneticsPsychotropic Drug PharmacokineticsRisperidone TherapyTherapeutic Dose Range
Steady state serum concentrations of risperidone and 9-hydroxyrisperidone (9-OH-risperidone), the active moiety, were measured in 42 patients. The concentration-to-dose ratios (C/D) varied by a factor of 20, from 1.8 to 36.8 (nmol/l)/(mg/24 hours), and 90% of the active moiety was constituted of 9-OH-risperidone. No correlation between the serum concentration of the active moiety and the side effects evaluated by the UKU Side Effect Scale was found. The absence of CYP2D6 (poor metabolizers) or the coadministration of drugs other than benzodiazepines increased the ratio between parent compound and metabolite but did not significantly influence the C/D of the total active moiety. A therapeutic range for serum risperidone has not been established, but 6 mg/day is considered the optimum dose for most patients. The authors found that in 90% of 22 patients administered 6 mg/day risperidone, the serum levels were within 50 to 150 nmol/l.
11
Risperidone in the treatment of schizophrenia
Stephen R. Marder, Richard C. Meibach · American Journal of Psychiatry · 1994 · 1.2K citations
Absorption, metabolism, and excretion of risperidone in humans.
Geert Mannens, Minxue Huang, W. Meuldermans et al. · Drug Metabolism and Disposition · 1993 · 261 citations